Bickerstaff George
Known title: DirectorCIK: 0001329646
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation. Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.
Transaction History
| CDNA | ▼ Sell | Open Market | 20,000 | $926K | 8/5/2026 | View on chart |
| CDNA | ▲ Buy | Grant | 9,795 | $0 | 6/12/2026 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 29,136 | $232K | 9/11/2025 | View on chart |
| CDNA | ▲ Buy | Grant | 12,103 | $0 | 6/13/2025 | View on chart |
| CDNA | ▼ Sell | Open Market | 20,000 | $367K | 3/10/2025 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 5,255 | $31K | 11/1/2024 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 2,226 | $12K | 11/1/2024 | View on chart |
| CDNA | ▲ Buy | Grant | 10,570 | $0 | 6/14/2024 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 5,255 | $53K | 5/14/2024 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 5,255 | $26K | 8/11/2023 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 9,745 | $48K | 8/11/2023 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 4,453 | $24K | 8/11/2023 | View on chart |
| CDNA | ▲ Buy | Grant | 18,844 | $0 | 6/16/2023 | View on chart |
| CDNA | ▲ Buy | Grant | 1,323 | $0 | 1/6/2023 | View on chart |
| CDNA | ▲ Buy | Option Exercise | 15,000 | $18K | 11/23/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 986 | $0 | 10/4/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 812 | $0 | 7/1/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 4,863 | $0 | 6/16/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 223 | $5K | 5/9/2022 | View on chart |
| INVA | ▲ Buy | Grant | 12,647 | $0 | 4/25/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 481 | $0 | 4/1/2022 | View on chart |
| CDNA | ▼ Sell | Open Market | 25,000 | $978K | 2/28/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 287 | $0 | 1/3/2022 | View on chart |
| CDNA | ▲ Buy | Grant | 196 | $0 | 10/1/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
CareDx shows high growth and fair‑value boost after reimbursement news
Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.
CareDx shows high growth and fair‑value boost after reimbursement news. Recent coverage noted CareDx’s strong revenue growth and improving fundamentals. Analyst updates cited new reimbursement information and target revisions, leading to a modest fair‑value increase. The company’s performance appears to be gaining attention among investors.